$0.78
0.93%
Nasdaq, Fri, Dec 27 2024
ISIN
US92023M1018
Symbol
VLON
Sector
Industry

Vallon Pharmaceuticals Inc Stock price

$0.78
+0.02 2.26% 1M
-1.18 60.35% 6M
-34.25 97.78% YTD
-30.55 97.52% 1Y
-16,270.02 100.00% 3Y
-20,528.82 100.00% 5Y
-20,528.82 100.00% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.01 0.93%
ISIN
US92023M1018
Symbol
VLON
Sector
Industry

Key metrics

Market capitalization $6.94m
Enterprise Value $2.32m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.07
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-8.31m
Free Cash Flow (TTM) Free Cash Flow $-12.17m
Cash position $4.75m
EPS (TTM) EPS $-51.88
Short interest 1.02%
Show more

Is Vallon Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Vallon Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Vallon Pharmaceuticals Inc forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Vallon Pharmaceuticals Inc forecast:

Buy
100%

Financial data from Vallon Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.02 0.02
-
-
-0.02 -0.02
-
-
- Selling and Administrative Expenses 4.29 4.29
59% 59%
-
- Research and Development Expense 3.99 3.99
151% 151%
-
-8.29 -8.29
31% 31%
-
- Depreciation and Amortization 0.02 0.02
-
-
EBIT (Operating Income) EBIT -8.31 -8.31
31% 31%
-
Net Profit -8.26 -8.26
36% 36%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vallon Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA.

Head office United States
CEO W. Hertz
Employees 4
Founded 2009
Website www.gribio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today